Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADI-001 in Treatment-Refractory Rheumatoid Arthritis
NCT07100873Phase 1Recruiting
- Sponsor
- Adicet Bio
- Start
- Oct 2025
- Primary completion
- Mar 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of prulacabtagene leucel in rheumatoid arthritis (RA) (5 arms), sponsored by Adicet Bio. Primary endpoint: Dose Limiting Toxicities at 28 days. Started Oct 2025; status: recruiting.
02
Drugs
prulacabtagene leucel
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT07100873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07100873.